Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This article aims to provide a comprehensive review of the current knowledge on the prevention and treatment of left ventricular outflow tract obstruction (LVOTO) associated with transcatheter mitral valve replacement-a novel and evolving treatment alternative for mitral regurgitation-encompassing both surgical and pharmacological interventions. LVOTO is a potentially catastrophic complication of transcatheter mitral valve replacement. Therefore, identifying patients at high risk for LVOTO and implementing a carefully tailored medical and surgical strategy are essential for optimizing perioperative management and improving patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2025.02.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcatheter edge-to-edge repair for the management of secondary mitral regurgitation - CRT 2025 Beyond the Guidelines.
Cardiovasc Revasc Med
August 2025
Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA. Electronic address:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios.
View Article and Find Full Text PDFSpanish cardiac catheterization and coronary intervention registry. 34 official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2024).
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
When Surgery Is Possible, Transcatheter Mitral Valve Replacement Should Not Be Plan A.
Ann Thorac Surg
September 2025
Department of Cardiac Surgery, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. Electronic address:
Late Survival and Self-reported Quality of Life in Octogenarians with Prior Sternotomy Undergoing Valvular Surgery.
Ann Thorac Surg
September 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota, USA. Electronic address:
Background: Recent advances in transcatheter valvular techniques often compete with open cardiac operations in managing high-risk patients with valvular disease, especially in the elderly. The present study assesses late survival and quality of life following valvular surgery in octogenarians with prior sternotomy.
Methods: We identified octogenarians who underwent cardiac valve reoperations between 2004 and 2023.
Comparison of Outcomes of Transcatheter Edge-to-Edge Repair With Early Versus Latest Generation MitraClip for Severe Mitral Regurgitation.
Heart Lung Circ
September 2025
Department of Cardiology, The Prince Charles Hospital, Brisbane, Qld, Australia; Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Herston, Qld, Australia.
Background: The fourth-generation MitraClip G4 system is the latest version of the transcatheter edge-to-edge repair (TEER) system for mitral regurgitation (MR).
Aim: This study aimed to evaluate the effectiveness of the MitraClip G4 in the reduction of MR compared to the early-generation MitraClip.
Method: We performed a retrospective analysis of consecutive patients undergoing TEER for MR with either the early-generation or newer-generation MitraClip G4 from a single-centre registry.